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Abstract
Background: Heart failure as recognized and treated in typical practice may represent a complex condition that
defies discrete categorizations. To illuminate this complexity, we examined treatment strategies for patients
hospitalized and treated for decompensated heart failure. We focused on the receipt of medications appropriate for
other acute conditions associated with shortness of breath including acute asthma, pneumonia, and exacerbated
chronic obstructive pulmonary disease.
Methods and Results: Using Premier Perspective®, we studied adults hospitalized with a principal discharge
diagnosis of heart failure and evidence of acute heart failure treatment from 2009-2010 at 370 US hospitals. We
determined treatment with acute respiratory therapies during the initial 2 days of hospitalization and daily during
hospital days 3-5. We also calculated adjusted odds of in-hospital death, admission to the intensive care unit, and
late intubation (intubation after hospital day 2). Among 164,494 heart failure hospitalizations, 53% received acute
respiratory therapies during the first 2 hospital days: 37% received short-acting inhaled bronchodilators, 33%
received antibiotics, and 10% received high-dose corticosteroids. Of these 87,319 hospitalizations, over 60%
continued receiving respiratory therapies after hospital day 2. Respiratory treatment was more frequent among the
60,690 hospitalizations with chronic lung disease. Treatment with acute respiratory therapy during the first 2 hospital
days was associated with higher adjusted odds of all adverse outcomes.
Conclusions: Acute respiratory therapy is administered to more than half of patients hospitalized with and treated for
decompensated heart failure. Heart failure is therefore regularly treated as a broader cardiopulmonary syndrome
rather than as a singular cardiac condition.
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Introduction
Although heart failure is the most common cause of
hospitalization for adults, it may in practice represent a more
complex and less distinct entity than has been appreciated.
While there has been growing recognition of multimorbidity [1]
and the complexities associated with treating coexisting chronic
conditions [2], scant attention has been paid to the degree to
which our current constructs of decompensated heart failure fit
with actual patterns of treatment. Accordingly, treatment
guidelines [3,4] and clinical textbooks [5–8] regularly describe
natural history and treatment from the perspective of a single
disease or condition. Moreover, heart failure registries [9–11]
and clinical investigations [12,13] have typically described the
use of neurohormonal-blocking agents, inotropes, diuretics,
and other cardiovascular agents without reporting on use of
non-cardiac pharmacotherapies. Yet hospitalized patients in
actual practice are complex, and their treatments may bridge
traditional categories due to diagnostic uncertainty or
coexisting acute illnesses [14].
In recent years, increasing attention has been dedicated to
understanding the overlap of cardiac and pulmonary diseases.
It has been shown that chronic lung and cardiac diseases are
closely related, as chronic airflow obstruction can impair left
ventricular filling, stroke volume, and cardiac output [15].
Moreover, the extent of pulmonary artery disease predicts both
right ventricular function and exacerbations of chronic
obstructive pulmonary disease [16]. These ties may carry over
to the acute setting, where pulmonary conditions such as
pneumonia can result in a spectrum of acute cardiac conditions
such as decompensated heart failure, arrhythmia, and acute
coronary syndromes [17].
Yet it is unknown how often patients hospitalized with
decompensated heart failure receive concomitant treatment
with acute respiratory therapies for conditions such as acute
asthma, pneumonia, and exacerbated chronic obstructive
pulmonary disease. Such co-treatment may be frequent in
typical practice, as presenting symptoms and signs of heart
failure are often non-specific [18,19] and are consistent with
common acute and chronic respiratory conditions that are also
frequently present [15,17,20,21]. Moreover, there is no singular
pathognomonic finding or diagnostic test that differentiates
heart failure from common respiratory conditions, which may
frequently contribute to uncertainty in diagnosis [22].
We therefore hypothesized that patients hospitalized with
decompensated heart failure would often receive concomitant
treatment with acute respiratory therapies. To test this
hypothesis, we investigated treatment strategies for patients
hospitalized and treated for decompensated heart failure,
focusing specifically on medications appropriate for other
common conditions associated with symptoms of shortness of
breath. Specifically, we sought to determine how often these
patients are treated for acute asthma, pneumonia, and
exacerbated chronic obstructive pulmonary disease, which may
represent the ambiguity of diagnosis or the presence of more
than 1 acute condition contributing to respiratory symptoms.
We also determined the duration of the concomitant treatments
and their association with adverse events. We characterized
these outcomes among all heart failure hospitalizations
meeting inclusion criteria as well as among the large [20] and
higher risk [23,24] subset with chronic lung disease who we
hypothesized would be even more likely to receive co-
treatment for acute cardiac and pulmonary conditions.
Methods
Ethics Statement
The Yale University Human Investigation Committee
reviewed the study protocol and determined that it was not
considered Human Subjects Research as defined by the Office
of Human Research Protections.
Data Source and Study Sample
We conducted a retrospective cohort study using
Perspective®, a voluntary, fee-supported database developed
by Premier, Inc. for measuring quality and healthcare
utilization. As of 2010, Perspective® contained data on more
than 130 million cumulative hospital discharges representing
approximately 20% of annual acute care hospitalizations in the
United States. In addition to information available in the
standard hospital discharge file, Perspective® contains a date-
stamped log of all billed items at the patient level including
diagnostic tests, medications, and therapeutic services.
Premier has de-identified patient data in accordance with the
United States Health Insurance Portability and Accountability
Act and assigned a random identifier to each hospital.
We included hospitalizations from 2009 and 2010 for patients
aged 18 years or older with a principal discharge diagnosis of
heart failure as defined by International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
codes 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13,
404.91, 404.93, and 428.xx). Although administrative codes are
highly specific for decompensated heart failure [25–27], we
sought to further increase the specificity of our study cohort by
requiring hospitalizations to be at least 2 days in duration and
include treatment with loop diuretics, intravenous vasodilators,
or inotropes during hospital days 1 or 2. We excluded
hospitalizations that involved transfers from another acute care
facility or that had an unknown admission source, as
information about treatment before hospitalization was
unavailable. We further excluded hospitalizations with a
pediatric attending to concentrate on care patterns of
physicians who treat adults.
Treatments
For each hospitalization, we noted treatment with commonly
used therapies for decompensated heart failure, acute asthma,
pneumonia, and exacerbated chronic obstructive pulmonary
disease. We chose to characterize treatments for these 3
respiratory conditions in particular, as they are among the most
common causes of hospitalization due primarily to breathing
difficulty [28]. For heart failure, we identified treatment with oral
and intravenous loop diuretics, intravenous vasodilators
including nitroglycerin, nitroprusside, and nesiritide, and
inotropes including dobutamine, dopamine, and milrinone. For
Cardiopulmonary Treatment of Heart Failure
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e78222
acute asthma, we noted use of short-acting inhaled
bronchodilators including β-agonists, anti-cholinergics, and
methylxanthine formulations. For pneumonia, we identified
treatment with antibiotics from pharmacologic classes used to
treat community-acquired and nosocomial pneumonia including
penicillins, cephalosporins, fluoroquinolones, macrolides,
vancomycin, tetracyclines, aminoglycosides, and
carbapenems. For exacerbated chronic obstructive pulmonary
disease, we identified daily corticosteroid treatments within a
dose range of 20mg to 80mg of oral prednisone or 120mg to
800mg of intravenous prednisone equivalents, as has been
done previously [29]. To increase the likelihood that antibiotics
and corticosteroids were intended for respiratory illness, we
used ICD-9-CM present-on-admission diagnosis codes to
exclude hospitalizations with evidence of common infections
besides pneumonia or inflammatory, allergic, or autoimmune
conditions other than exacerbated chronic obstructive
pulmonary disease (Tables S1 and S2 in File S1).
Treatment Groups
We assigned admissions to 1 of 5 treatment groups based
on respiratory medications of interest that were dispensed
during the first 2 days of hospitalization. Treatment groups
were structured around potential treatment regimens for acute
asthma, pneumonia or exacerbated chronic obstructive
pulmonary disease as described by clinical guidelines or found
in common use [30–33]. Treatment groups were also mutually
exclusive and exhaustive, meaning that all hospitalizations
meeting study inclusion criteria were able to be categorized
into 1 of these 5 groups. These 5 initial treatment groups were
defined by the receipt of (1) heart failure treatment only; (2)
heart failure treatment plus inhaled bronchodilators only; (3)
heart failure treatment plus antibiotics with or without inhaled
bronchodilators; (4) heart failure treatment plus corticosteroids
with or without inhaled bronchodilators; and (5) heart failure
treatment plus antibiotics and corticosteroids with or without
inhaled bronchodilators (Figure 1).
To better understand the use of respiratory treatments over
the period of hospitalization, we assigned each patient to a
continuing treatment group if treatments were received each
day during hospital days 3 through 5 or on the day of
discharge, whichever occurred first. These 5 continuing
treatment categories, which were also mutually exclusive and
exhaustive, were (1) discharge after hospital day 2 (ineligible
for continuing therapy); (2) no daily heart failure or respiratory
treatments during days 3 through 5; (3) heart failure treatment
only; (4) acute respiratory treatment only; and (5) heart failure
treatment plus acute respiratory treatment (Figure 1). We
assigned patients to longitudinal treatment pathways based on
their combination of treatment during hospital days 1 to 2 and 3
through 5.
For interested readers, further subdivision of continuing
treatment categories for (1) acute respiratory treatment only
Figure 1.  Longitudinal treatment pathways.  A sample pathway is shown for a patient who receives treatment for heart failure
and bronchodilators during the first 2 hospital days and acute respiratory treatment only during hospital days 3 through 5. Acute
respiratory treatment includes treatment with short-acting inhaled bronchodilators, antibiotics, or corticosteroids. Within each time
period, treatment groups are mutually exclusive and inclusive of all patients.
HF, heart failure.
doi: 10.1371/journal.pone.0078222.g001
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and (2) heart failure treatment plus acute respiratory treatment
is described in Figure S1 in File S1.
Outcomes
Our primary outcome was the percentage of heart failure
hospitalizations that received common heart failure
pharmacotherapies plus other respiratory therapies during the
initial 2 hospital days. The consistency of findings was tested in
subgroup analyses. We also noted heart failure and respiratory
treatments dispensed daily during hospital days 3 through 5 for
patients in each of the 5 initial treatment groups to characterize
the relative frequency of different longitudinal treatment
pathways.
Secondary outcomes for each initial treatment group
included in-hospital death, admission to an intensive care unit,
and late intubation (intubation 2 or more days after admission).
All analyses were repeated for the subgroup of patients with
chronic lung disease as defined by Elixhauser and colleagues
[34] to predominantly include chronic asthma and chronic
obstructive pulmonary disease.
Statistical Analyses
We calculated summary statistics for categorical variables
using frequencies and percentages. Hierarchical logistic
regression was used to calculate adjusted odds ratios for all
outcomes. We used all hospitalizations when calculating odds
ratios for admission to an intensive care unit and late
intubation. We used 1 random hospitalization per patient when
calculating odds ratios for in-hospital mortality, as death could
only occur once. We adjusted for patient characteristics and
Elixhauser comorbidities, with the exception of heart failure and
chronic lung disease. Comorbidities were identified with
software provided by the Healthcare Cost and Utilization
Project of the Agency for Healthcare Research and Quality
(versions 3.4, 3.5, and 3.6 for federal fiscal years 2009, 2010
and 2011, respectively) [34]. We calculated odds ratios and
95% confidence intervals for each outcome using as the
referent the group initially receiving heart failure treatment only.
Analyses were conducted with SAS 9.2 (SAS Institute Inc.,
Cary, NC).
Results
We identified 164,494 qualifying hospitalizations for heart
failure among 370 hospitals. We did not include 26,382
hospitalizations with a principal discharge diagnosis of heart
failure that failed to meet minimum length of stay requirements
and a further 18,319 hospitalizations that did not meet
treatment requirements. Among the 164,494 qualifying
hospitalizations, we identified 127,410 unique patients, of
whom 103,534 (81%) were hospitalized once, 16,442 (13%)
were hospitalized twice, and 7,434 (6%) were hospitalized 3 or
more times.
Of 164,494 qualifying heart failure hospitalizations, 63,690
(39%) had chronic lung disease (Table 1). Among the 63,690
qualifying heart failure hospitalizations with chronic lung
disease, we identified 50,982 unique patients, of whom 42,685
(84%) were hospitalized once, 5,765 (11%) were hospitalized
twice, and 2,532 (5%) were hospitalized 3 or more times.
Patients with chronic lung disease were very similar in age,
sex, and comorbidity profile to the overall heart failure cohort,
though were more often obese (Table 1).
Acute respiratory therapy was common throughout
hospitalization. Among our primary sample of all heart failure
hospitalizations, 53% and 49% received treatment with at least
1 acute respiratory therapy during the first 2 hospital days and
hospital days 3 through 5, respectively. Among heart failure
hospitalizations with chronic lung disease, 73% and 67%
received treatment with at least 1 acute respiratory therapy
during the first 2 hospital days and hospital days 3 through 5,
respectively.
Treatment with short-acting inhaled bronchodilators and
antibiotics was particularly frequent. Among the cohort of all
heart failure hospitalizations, 37% and 30% received treatment
with short-acting inhaled bronchodilators during the first 2
hospital days and hospital days 3 through 5, respectively
(Figure 2A). Among the subset with chronic lung disease, 59%
and 50% received treatment with short-acting inhaled
bronchodilators during the first 2 hospital days and hospital
days 3 through 5, respectively (Figure 2B). Inhaled beta
agonists were the most frequently used agents in both cohorts









  N (%) N (%)
Age 18-54 19,596 (12) 6,266 (10)
 55-64 23,670 (14) 9,927 (16)
 65-74 33,757 (21) 15,368 (24)
 75-84 47,392 (29) 19,438 (31)
 85+ 40,079 (24) 12,691 (20)
Sex Female 81,298 (49) 31,317 (49)




Vascular Disease 22,344 (14) 10,218 (16)





76,313 (46) 30,380 (48)





63,690 (39) 63,690 (100)





49,680 (30) 20,158 (32)
 DeficiencyAnemias 54,237 (33) 21,824 (34)
 Liver Disease 4,112 (3) 1,612 (3)
 Depression 16,639 (10) 7,607 (12)
doi: 10.1371/journal.pone.0078222.t001
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during both time periods (Table S3 in File S1). Analogously,
among the cohort of all heart failure hospitalizations,
approximately one-third received antibiotics during both time
periods (Figure 2A). Among heart failure hospitalizations with
chronic lung disease, 42% received antibiotics during both time
periods (Figure 2B). The most commonly used antibiotic
pharmacologic classes were fluoroquinolones and
cephalosporins in both cohorts during both time periods (Table
S3 in File S1). Although corticosteroids were the least
frequently used of all studied acute respiratory therapies, we
did find that 17% of hospitalizations with chronic lung disease
received high-dose corticosteroids during the first 2 hospital
days (Table S3 in File S1).
Further subgroup analyses demonstrated the consistency of
findings across diverse populations (Table S4 in File S1). We
found that at least 47% of patients received respiratory
treatment during the first 2 days of hospitalization regardless of
age. The rate of initial co-treatment remained 41% even in
those without chronic lung disease. More than 50% of patients
received initial respiratory treatment regardless of whether daily
loop diuretics were given during only the first 2 hospital days or
through day 5 of hospitalization. Analogously, rates of initial co-
treatment were above 50% whether or not early diagnostic
testing with natriuretic peptides was performed and above 43%
whether or not early diagnostic testing with chest radiographs
was performed.
Figure 3 describes the diversity of longitudinal treatment
strategies for the entire sample of heart failure hospitalizations
(n=164,494). Among the 77,175 hospitalizations that received
initial treatment only for heart failure, less than 1% initiated
daily respiratory treatment after hospital day 2. Among the
27,980 hospitalizations with initial heart failure and
bronchodilator treatment, at least 1 respiratory treatment was
continued daily after hospital day 2 in almost 50% of cases.
Analogously, among the 44,846 hospitalizations receiving initial
heart failure and antibiotic treatment, daily respiratory therapy
was continued after hospital day 2 in 66% of cases. Finally,
among the 8,641 hospitalizations receiving initial treatment with
both antibiotics and corticosteroids, 81% continued to receive
daily respiratory treatment after hospital day 2. Overall, among
the 87,319 hospitalizations initially receiving respiratory
treatment during the first 2 hospital days, more than 60%
(n=53,615) continued to receive at least 1 respiratory treatment
on a daily basis after day 2. For interested readers, greater
detail about specific respiratory treatments received after
hospital day 2 is presented in Table S5 in File S1.
Notably, among hospitalizations receiving at least 1 initial
respiratory treatment, 18% continued to receive daily
respiratory therapies in the absence of daily heart failure
therapy after hospital day 2. For example, 19% of
hospitalizations that initially received antibiotics with or without
bronchodilators continued receiving daily respiratory therapy in
the absence of daily treatment for heart failure after hospital
day 2 (Table S5 in File S1).
Observed rates of adverse outcomes among all heart failure
hospitalizations were 2% for in-hospital death, 17% for
admission to an intensive care unit, and 3% for late intubation.
The median length of stay was 4 days (interquartile range 3, 7).
Observed rates of adverse outcomes among heart failure
hospitalizations with chronic lung disease were 3% for in-
hospital death, 18% for admission to an intensive care unit, and
4% for late intubation. The median length of stay was 5 days
(interquartile range 3, 7).
Adjusted odds for adverse outcomes consistently
demonstrated an association between hospitalizations
involving initial respiratory treatment and higher in-hospital
mortality, admission to an intensive care unit, and late
intubation compared with hospitalizations receiving only heart
failure treatment. For example, among the cohort of all heart
failure hospitalizations (Table 2), adjusted odds ratios with
corresponding 95% confidence intervals for inpatient death
were 1.74 (1.60, 1.88) and 2.04 (1.78, 2.34) for hospitalizations
involving heart failure treatment plus antibiotics and heart
failure treatment plus antibiotics and corticosteroids,
respectively. Analogously, among the subset of heart failure
hospitalizations with chronic lung disease (Table 3), adjusted
odds ratios for inpatient death were 1.34 (1.17, 1.54) and 1.63
(1.36, 1.95) for hospitalizations involving heart failure treatment
plus antibiotics and heart failure treatment plus antibiotics and
corticosteroids, respectively. We similarly found that the
adjusted odds of admission to an intensive care unit and late
intubation were higher among patients receiving initial
respiratory treatment in both the entire cohort of heart failure
hospitalizations and the subgroup with chronic lung disease
(Tables 2 and 3, respectively).
Discussion
Our study characterizes the substantial extent to which
patients hospitalized with and treated for decompensated heart
failure also receive therapy for acute respiratory conditions.
Most patients receive acute respiratory therapies including
short-acting inhaled bronchodilators, antibiotics, and
corticosteroids during the first 2 hospital days. Slightly less than
half of patients are treated exclusively for heart failure. When
given early during hospitalization, respiratory therapies are
continued after day 2 more than 60% of the time. These
significant rates of co-treatment for acute cardiac and
respiratory conditions were even higher among the large
subset of patients with chronic lung disease. Over 70% of
these patients received at least 1 acute respiratory therapy
during hospitalization. These findings demonstrate that in
typical practice within the United States, in contradistinction to
contemporary teaching, heart failure is regularly treated as a
broader cardiopulmonary syndrome rather than as a singular
cardiac condition. The reasons underlying these treatment
patterns and their appropriateness will require further
explication.
Co-treatment for acute cardiac and pulmonary disease
appears to be a widespread phenomenon across diverse
patient subgroups hospitalized with decompensated heart
failure. For example, regardless of age and likelihood of having
left ventricular systolic dysfunction [35], approximately 50% of
hospitalizations involved treatment with acute respiratory
therapy. More than 40% of hospitalizations involved respiratory
therapy even in the absence of comorbid chronic lung disease.
Cardiopulmonary Treatment of Heart Failure
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Figure 2.  Proportion of hospitalizations receiving short-acting inhaled bronchodilators, antibiotics, and high-dose
corticosteroids during the first 2 hospital days and hospital days 3 through 5.  Figure A shows results for all heart failure
hospitalizations (n=164,494). Figure B shows results for heart failure hospitalizations with chronic lung disease (n=60,690).
HF, heart failure.
doi: 10.1371/journal.pone.0078222.g002
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Perhaps most importantly, co-treatment rates were not different
between patients treated with loop diuretics throughout
hospitalization and those who did not receive these agents on
a daily basis after hospital day 2, implying that the extent of
volume overload was not clearly associated with the decision to
broaden treatment to include respiratory therapies.
Our findings suggest several possible explanations for the
high frequency of co-treatment, all of which illustrate the
complexity of heart failure in typical practice. First, it is possible
that clinical presentation was often non-specific, as acute
respiratory therapy was stopped after hospital day 2 in more
than 20% of hospitalizations, presumably because an
underlying diagnosis of heart failure became more apparent.
This difficulty in differentiating heart failure from other
conditions that cause respiratory symptoms is further
evidenced by the fact that rates of co-treatment were above
50% even among patients who underwent early diagnostic
testing with natriuretic peptides or chest radiographs. Second,
many patients may have had evidence of true coexisting acute
cardiac and pulmonary conditions, as respiratory treatment was
regularly continued beyond the first 2 hospital days and was
also associated with higher adverse outcomes including
mortality. For these patients, the signs and symptoms of acute
illness may have defied easy description, and there may have
been evidence of more than 1 condition with an uncertain
pathophysiologic basis. Yet our findings cannot determine the
reasons for co-treatment or the appropriateness of this
treatment strategy. Further study will be needed to elucidate
the motivations for administering acute respiratory treatment to
patients with suspected heart failure and the influence of
comorbid lung disease on treatment choices.
Additional study is also needed to understand the benefits
and harms of acute respiratory treatment in the heart failure
population including potential differences in treatment effects
for persons with chronic pulmonary disease. For example, it is
unknown whether bronchodilators improve symptoms in
persons with dyspnea stemming exclusively from acute heart
failure as they may in patients with chronic heart failure [36,37].
It is also uncertain as to whether beta agonists in particular
may have positive hemodynamic effects in the acute setting as
has been shown in chronic disease [36,38]. These salutatory
effects may be counter-balanced by an increased likelihood of
Figure 3.  Daily treatment during hospital days 3 through 5 for patients in each initial treatment group.  Percentages reflect
the division of patients within each of the 5 initial treatment groups into 1 of 5 continuing treatment pathways. Pathways are mutually
exclusive and exhaustive of all patients within the study sample. Non-labeled categories have percentages less than 5%. The 5
initial treatment groups were defined by the receipt during the first 2 hospital days of (1) heart failure treatment only (HF only); (2)
heart failure treatment plus inhaled bronchodilators only (HF + Bronchodilators); (3) heart failure treatment plus antibiotics with or
without inhaled bronchodilators (HF + Antibiotics (± Bronchodilators)); (4) heart failure treatment plus corticosteroids with or without
inhaled bronchodilators (HF + Corticosteroids (± Bronchodilators)); or (5) heart failure treatment plus antibiotics and corticosteroids
with or without inhaled bronchodilators (HF + Antibiotics + Corticosteroids (± Bronchodilators)). Treatment during hospital days 3
through 5 could fall into 1 of the 5 following categories: (1) discharge after hospital day 2 so ineligible for continuing therapy; (2) no
daily heart failure or respiratory treatments during days 3 through 5; (3) daily heart failure treatment only (HF only); (4) daily acute
respiratory treatment only (RT only); and (5) daily heart failure treatment plus daily acute respiratory treatment (HF + RT).
HF, heart failure; RT, respiratory therapy.
doi: 10.1371/journal.pone.0078222.g003
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arrhythmias [39], ischemia [40], or possible long term adverse
consequences from sympathetic stimulation [41]. The effects of
beta agonist therapy may also relate to the concomitant use of
cardioselective as compared with non-cardioselective beta
blockers [42]. Analogously, corticosteroid administration may
result in enhanced diuresis among patients who are diuretic
resistant [43]. However, glucocorticoids may also cause
arrhythmias [44] and ischemic events [45]. Antibiotics can
result in harmful drug interactions with commonly used cardiac
Table 2. Odds Ratios for Adjusted Outcomes by Treatment
During the First 2 Hospital Days for All Heart Failure
Hospitalizations.
Treatment During First 2
Hospital Days
Adjusted Outcomes by Treatment Group for All
Heart Failure Hospitalizations (N=164,494)
 Odds Ratio (95% CI)
 
In-Hospital
Mortality ICU admission Late Intubation
HF Only -- -- --
HF + Bronchodilators 1.56 (1.41,1.73) 1.27 (1.22, 1.33) 1.35 (1.24, 1.46)
HF + Antibiotics (±
Bronchodilators)
1.74 (1.60,
1.88) 1.74 (1.68, 1.80) 1.76 (1.65, 1.88)
HF + Corticosteroids (±
Bronchodilators)
1.40 (1.16,
1.71) 1.44 (1.33, 1.55) 1.33 (1.15, 1.54)




2.34) 2.03 (1.91, 2.16) 1.85 (1.65, 2.07)
HF: heart failure; ICU: intensive care unit.
doi: 10.1371/journal.pone.0078222.t002
Table 3. Odds Ratios for Adjusted Outcomes by Treatment
During the First 2 Hospital Days for Heart Failure
Hospitalizations with Chronic Lung Disease.
Treatment During First
2 Hospital Days
Adjusted Outcomes by Treatment Group for Heart
Failure Hospitalizations with Chronic Lung Disease
(N=63,690)
 Odds Ratio (95% CI)
 
In-Hospital
Mortality* ICU admission Late Intubation
HF Only -- -- --
HF + Bronchodilators 1.24 (1.06,1.45) 1.14 (1.07, 1.22) 1.11 (0.99, 1.25)
HF + Antibiotics (±
Bronchodilators)
1.34 (1.17,
1.54) 1.71 (1.61, 1.81) 1.51 (1.36, 1.67)
HF + Corticosteroids (±
Bronchodilators)
1.33 (1.04,
1.68) 1.32 (1.20, 1.46) 1.16 (0.97, 1.38)




1.95) 1.87 (1.73, 2.02) 1.60 (1.40, 1.83)
HF: heart failure; ICU: intensive care unit.
*. Variables selected for in-hospital mortality model using step-wise selection.
doi: 10.1371/journal.pone.0078222.t003
medications [46] and severe nosocomial infections [47].
Potential harms may explain our finding consistent association
of acute respiratory treatment with adverse outcomes. It may
also be that patients receiving acute respiratory treatment are
inherently more complex with greater severity of illness. These
associations are therefore primarily hypothesis generating and
merit prospective testing given the sizable numbers of heart
failure patients co-treated for acute cardiac and pulmonary
disease. At this time, acute respiratory treatment can at best be
considered a marker of risk among heart failure
hospitalizations.
Do the treatment patterns represent miscoding of heart
failure? This possibility seems unlikely, as all patients were
required to have treatments for heart failure, findings were
consistent across subgroups defined by patient characteristics,
diagnostic testing strategies, and interventions, and the number
of patients broadly treated was far too large to plausibly result
primarily from inaccurate coding. Moreover, studies have found
ICD-9-CM codes for heart failure to be more than 95% specific
with high positive predictive value relative to chart review or
clinical assessment [25–27]. These codes have been used to
identify epidemiologic trends in heart failure hospitalization [48]
and evaluate hospital performance for the purposes of public
reporting [49–51]. Moreover, ICD-9-CM codes for heart failure
may be more specific than commonly used diagnostic criteria
for decompensated heart failure including the Framingham,
modified Boston, and Gothenburg indices [52]. Finally, our
resultant cohort was similar to the patient population in a large
dedicated heart failure registry with regard to patient
comorbidities, use of intravenous loop diuretics, admission to
the intensive care unit, and average length of stay [9–11].
A number of issues merit consideration when interpreting our
results. First, our administrative database lacked information on
vital signs, results of laboratory testing, left ventricular ejection
fraction, and medication use both before and after
hospitalization, thereby limiting our ability to define the reasons
for respiratory treatment, its association with cardiac structural
dysfunction, and the relationship of acute respiratory therapies
with baseline treatment strategies. However, our objective was
to define inpatient patterns of treatment, and this database is
ideal for that purpose. Second, as we assessed a broad list of
antibiotics that could be used for the treatment of pneumonia, it
is possible that they were used for a different purpose.
Nevertheless, we may have actually underestimated overall
antibiotic and corticosteroid use in the inpatient treatment of
patients with heart failure, as we excluded hospitalizations that
had evidence of common infections besides pneumonia and
inflammatory, allergic, or autoimmune conditions other than
exacerbated chronic obstructive pulmonary disease. Third,
short-acting inhaled bronchodilators may have been used for
patient comfort or wheezing (cardiac asthma) in the setting of
dyspnea rather than for treatment of another entity. However,
usage of inhaled bronchodilators for this indication would not
be consistent with heart failure guidelines [3,4]. Fourth, despite
their wide geographic distribution and diverse range of
structural characteristics, it is possible that hospitals in the
Premier network are not generalizable to all US hospitals. Fifth,
it may be that heart failure hospitalizations in the Perspective®
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database are not adequately representative of all US heart
failure hospitalizations. However, we found that patient
characteristics, treatments received, and in-hospital outcomes
among our study cohort are similar to that of hospitalizations
within a large and well-respected US heart failure registry
[9–11]. Finally, it remains possible that our estimates of acute
respiratory treatment were biased upward by the inclusion of
patients with primary respiratory conditions rather than
decompensated heart failure. However, our estimates of co-
treatment are sufficiently high to make it implausible that acute
respiratory treatment is simply a byproduct of misclassification.
Even if our findings were adjusted downward by a factor of 2,
we would still find that over one-quarter of all heart failure
hospitalizations and one-third of heart failure hospitalizations
with chronic lung disease receive acute respiratory treatment
during hospitalization.
We have demonstrated for the first time in a large study
across many institutions that treatment with acute respiratory
therapies occurs in more than one-half of patients hospitalized
with decompensated heart failure. When started early during
hospitalization, these respiratory treatments are continued after
day 2 in the majority of cases. Rates of acute respiratory
treatment are even higher among the large subgroup of
patients with a history of chronic lung disease. These findings
demonstrate that patients with heart failure are regularly
treated with a broader cardiopulmonary treatment strategy
throughout hospitalization. Further prospective investigation will
be needed to better understand the motivations for this
common approach to treatment and the extent to which it
impacts patient outcomes.
Supporting Information
File S1.  Contains Tables S1-S5 and Figure S1. Table S1.
Infections Other Than Pneumonia Potentially Requiring
Antibiotic Treatment.
Table S2. Conditions Other Than Exacerbated Chronic
Obstructive Pulmonary Disease Potentially Requiring High-
Dose Steroid Treatment.
Figure S1. Longitudinal Treatment Pathways. A sample
pathway is shown for a patient who receives treatment for heart
failure and bronchodilators during the first 2 hospital days and
bronchodilators only during hospital days 3 through 5. Within
each time period, treatment groups are mutually exclusive and
inclusive of all patients. HF, heart failure.
Table S3. Treatments Received During the First 2 Hospital
Days and Hospital Days 3 through 5.
Table S4. Acute Respiratory Treatment During the First Two
Days of Hospitalization by Patient Subgroup.
Table S5. Longitudinal Treatment Pathways: Treatment During




Conceived and designed the experiments: KD KMS TL PKL
MET JL SL HMK. Performed the experiments: KD KMS SL
HMK. Analyzed the data: KD KMS TL PKL MET JL SL HMK.
Contributed reagents/materials/analysis tools: KD TL PKL
HMK. Wrote the manuscript: KD HMK.
References
1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S et al. (2012)
Epidemiology of multimorbidity and implications for health care,
research, and medical education: a cross-sectional study. Lancet 380:
37-43. doi:10.1016/S0140-6736(13)60393-1. PubMed: 22579043.
2. Boyd CM, Darer J, Boult C, Fried LP, Boult L et al. (2005) Clinical
practice guidelines and quality of care for older patients with multiple
comorbid diseases: implications for pay for performance. JAMA 294:
716-724. doi:10.1001/jama.294.6.716. PubMed: 16091574.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS et al.
(2009) 2009 focused update incorporated into the ACC/AHA 2005
Guidelines for the Diagnosis and Management of Heart Failure in
Adults: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines:
developed in collaboration with the International Society for Heart and
Lung Transplantation. Circulation 119: e391-e479. doi:10.1161/
CIRCULATIONAHA.109.192065. PubMed: 19324966.
4. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P
et al. (2008) ESC guidelines for the diagnosis and treatment of acute
and chronic heart failure 2008: the Task Force for the diagnosis and
treatment of acute and chronic heart failure 2008 of the European
Society of Cardiology. Developed in collaboration with the Heart Failure
Association of the ESC (HFA) and endorsed by the European Society
of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989. doi:
10.1016/j.ejheart.2008.08.005. PubMed: 18826876.
5. Mann DL, Chakinala M (2011) Heart failure and cor pulmonale. In:
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL et al.,
editors. Harrison's Principles of Internal Medicine. 18th ed. New York,
NY: McGraw-Hill Companies. pp. 1901-1915.
6. McMurray JJ, Pfeffer MA (2012) Heart failure: management and
prognosis. In: Goldman L, Schafer AI, editors. Goldman's Cecil
Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier. pp. 303-318.
7. Teerlink JR (2008) Diagnosis and management of acute heart failure.
In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's Heart
Disease: a Textbook of Cardiovascular Medicine. 8th ed. Philadelphia,
PA: Saunders Elsevier. pp. 583-610.
8. Abraham WT, Hasan A (2010) Diagnosis and management of heart
failure. In: Fuster V, Walsh RA, Harrington RA, editors. Hurst's The
Heart. 13th ed. New York, NY: McGraw-Hill Companies. pp. 748-780.
9. Adams KF Jr., Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR
et al. (2005) Characteristics and outcomes of patients hospitalized for
heart failure in the United States: rationale, design, and preliminary
observations from the first 100,000 cases in the Acute Decompensated
Heart Failure National Registry (ADHERE). Am Heart J 149: 209-216.
doi:10.1016/j.ahj.2004.08.005. PubMed: 15846257.
10. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC
(2006) Clinical presentation, management, and in-hospital outcomes of
patients admitted with acute decompensated heart failure with
preserved systolic function: a report from the Acute Decompensated
Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol
47: 76-84. doi:10.1016/j.jacc.2005.09.022. PubMed: 16386668.
11. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW
(2007) Temporal trends in clinical characteristics, treatments, and
outcomes for heart failure hospitalizations, 2002 to 2004: findings from
Acute Decompensated Heart Failure National Registry (ADHERE). Am
Heart J 153: 1021-1028. doi:10.1016/j.ahj.2007.03.012. PubMed:
17540205.
12. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K
et al. (2011) Effect of nesiritide in patients with acute decompensated
heart failure. N Engl J Med 365: 32-43. doi:10.1056/NEJMicm1014605.
PubMed: 21732835.
13. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW et al. (2011)
Diuretic strategies in patients with acute decompensated heart failure.
N Engl J Med 364: 797-805. doi:10.1056/NEJMoa1005419. PubMed:
21366472.
14. Lichtman JH, Fathi A, Radford MJ, Lin Z, Loeser CS et al. (2006)
Acute, severe noncardiac conditions in patients with acute myocardial
Cardiopulmonary Treatment of Heart Failure
PLOS ONE | www.plosone.org 9 October 2013 | Volume 8 | Issue 10 | e78222
infarction. Am J Med 119: 843-850. doi:10.1016/j.amjmed.2006.03.040.
PubMed: 17000215.
15. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL et al. (2010)
Percent emphysema, airflow obstruction, and impaired left ventricular
filling. N Engl J Med 362: 217-227. doi:10.1056/NEJMoa0808836.
PubMed: 20089972.
16. Wells JM, Washko GR, Han MK, Abbas N, Nath H et al. (2012)
Pulmonary arterial enlargement and acute exacerbations of COPD. N
Engl J Med 367: 913-921. doi:10.1056/NEJMoa1203830. PubMed:
22938715.
17. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L et al.
(2012) Cardiac complications in patients with community-acquired
pneumonia: incidence, timing, risk factors, and association with short-
term mortality. Circulation 125: 773-781. doi:10.1161/
CIRCULATIONAHA.111.040766. PubMed: 22219349.
18. Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C et al. (2006)
Acute respiratory failure in the elderly: etiology, emergency diagnosis
and prognosis. Crit Care 10: R82. doi:10.1186/cc4926. PubMed:
16723034.
19. Delerme S, Ray P (2008) Acute respiratory failure in the elderly:
diagnosis and prognosis. Age Ageing 37: 251-257. doi:10.1093/ageing/
afn060. PubMed: 18388161.
20. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL et al.
(2002) Spectrum of heart failure in older patients: results from the
National Heart Failure project. Am Heart J 143: 412-417. doi:10.1067/
mhj.2002.120773. PubMed: 11868045.
21. Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S et al.
(2011) Cardiac complications in patients with community-acquired
pneumonia: a systematic review and meta-analysis of observational
studies. PLOS Med 8: e1001048. PubMed: 21738449.
22. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG et al.
(2009) Heart failure and chronic obstructive pulmonary disease:
diagnostic pitfalls and epidemiology. Eur J Heart Fail 11: 130-139. doi:
10.1093/eurjhf/hfn013. PubMed: 19168510.
23. Mentz RJ, Fiuzat M, Wojdyla DM, Chiswell K, Gheorghiade M et al.
(2012) Clinical characteristics and outcomes of hospitalized heart
failure patients with systolic dysfunction and chronic obstructive
pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail 14:
395-403. doi:10.1093/eurjhf/hfs009. PubMed: 22302663.
24. Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O'Connor CM et al.
(2012) The impact of chronic obstructive pulmonary disease in patients
hospitalized for worsening heart failure with reduced ejection fraction:
an analysis of the EVEREST Trial. J Card Fail 18: 515-523. doi:
10.1016/j.cardfail.2012.04.010. PubMed: 22748484.
25. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ et al.
(2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and
stroke risk factors. Med Care 43: 480-485. doi:10.1097/01.mlr.
0000160417.39497.a9. PubMed: 15838413.
26. Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI et al. (2008)
Assessing validity of ICD-9-CM and ICD-10 administrative data in
recording clinical conditions in a unique dually coded database. Health
Serv Res 43: 1424-1441. doi:10.1111/j.1475-6773.2007.00822.x.
PubMed: 18756617.
27. Kümler T, Gislason GH, Kirk V, Bay M, Nielsen OW et al. (2008)
Accuracy of a heart failure diagnosis in administrative registers. Eur J
Heart Fail 10: 658-660. doi:10.1016/j.ejheart.2008.05.006. PubMed:
18539522.
28. Agency for Healthcare Research and Quality (2006) Statistical brief 2:
reasons for being admitted to the hospital through the emergency
department, 2003, Healthcare Cost and Utilization Project (HCUP).
Available: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb2.pdf.
Accessed 25 April 2013.
29. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM et al. (2010)
Association of corticosteroid dose and route of administration with risk
of treatment failure in acute exacerbation of chronic obstructive
pulmonary disease. JAMA 303: 2359-2367. doi:10.1001/jama.
2010.796. PubMed: 20551406.
30. (2007) Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis
and management of asthma-summary report 2007. J Allergy Clin
Immunol 120: S94-138
31. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD et al.
(2007) Infectious Diseases Society of America/American Thoracic
Society consensus guidelines on the management of community-
acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2: S27-S72. doi:
10.1086/511159. PubMed: 17278083.
32. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011)
Global strategy for the diagnosis, management, and prevention of;
COPD. Available: http://www.goldcopd.org/uploads/users/files/
GOLD_Report_2011_Feb21.pdf. Accessed 25 April 2013.
33. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ et al. (2010)
Antibiotic therapy and treatment failure in patients hospitalized for acute
exacerbations of chronic obstructive pulmonary disease. JAMA 303:
2035-2042. doi:10.1001/jama.2010.672. PubMed: 20501925.
34. Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity
measures for use with administrative data. Med Care 36: 8-27. doi:
10.1097/00005650-199801000-00004. PubMed: 9431328.
35. Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and
diastolic heart failure: Part I: diagnosis, prognosis, and measurements
of diastolic function. Circulation 105: 1387-1393. doi:10.1161/
hc1102.105289. PubMed: 11901053.
36. Uren NG, Davies SW, Jordan SL, Lipkin DP (1993) Inhaled
bronchodilators increase maximum oxygen consumption in chronic left
ventricular failure. Eur Heart J 14: 744-750. doi:10.1093/eurheartj/
14.6.744. PubMed: 8325299.
37. Witte KK, Morice A, Cleland JG, Clark AL (2004) The reversibility of
increased airways resistance in chronic heart failure measured by
impulse oscillometry. J Card Fail 10: 149-154. doi:10.1016/j.cardfail.
2003.08.007. PubMed: 15101027.
38. Slutsky R (1981) Hemodynamic effects of inhaled terbutaline in
congestive heart failure patients without lung disease: beneficial
cardiotonic and vasodilator beta-agonist properties evaluated by
ventricular catheterization and radionuclide angiography. Am Heart J
101: 556-560. doi:10.1016/0002-8703(81)90221-0. PubMed: 7223595.
39. Salpeter SR, Ormiston TM, Salpeter EE (2004) Cardiovascular effects
of beta-agonists in patients with asthma and COPD: a meta-analysis.
Chest 125: 2309-2321. doi:10.1378/chest.125.6.2309. PubMed:
15189956.
40. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM (2000) The risk of
myocardial infarction associated with inhaled beta-adrenoceptor
agonists. Am J Respir Crit Care Med 161: 827-830. doi:10.1164/ajrccm.
161.3.9904006. PubMed: 10712329.
41. Felker GM, O'Connor CM (2001) Inotropic therapy for heart failure: an
evidence-based approach. Am Heart J 142: 393-401. doi:10.1067/mhj.
2001.117606. PubMed: 11526351.
42. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM et al.
(2011) Heart failure and chronic obstructive pulmonary disease the
quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 57:
2127-2138. doi:10.1016/j.jacc.2011.02.020. PubMed: 21596228.
43. Liu C, Liu G, Zhou C, Ji Z, Zhen Y et al. (2007) Potent diuretic effects of
prednisone in heart failure patients with refractory diuretic resistance.
Can J Cardiol 23: 865-868. doi:10.1016/S0828-282X(07)70840-1.
PubMed: 17876376.
44. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat
RD et al. (2009) Glucocorticoid use and risk of atrial fibrillation or flutter:
a population-based, case-control study. Arch Intern Med 169:
1677-1683. doi:10.1001/archinternmed.2009.297. PubMed: 19822824.
45. Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by
prescription is associated with subsequent cardiovascular disease. Ann
Intern Med 141: 764-770. doi:
10.7326/0003-4819-141-10-200411160-00007. PubMed: 15545676.
46. Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions
in the elderly: a review. Am J Geriatr Pharmacother 9: 364-377. doi:
10.1016/j.amjopharm.2011.10.004. PubMed: 22078863.
47. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S et al. (2011)
Host and pathogen factors for Clostridium difficile infection and
colonization. N Engl J Med 365: 1693-1703. doi:10.1056/
NEJMoa1012413. PubMed: 22047560.
48. Chen J, Normand SL, Wang Y, Krumholz HM (2011) National and
regional trends in heart failure hospitalization and mortality rates for
Medicare beneficiaries, 1998-2008. JAMA 306: 1669-1678. doi:
10.1001/jama.2011.1474. PubMed: 22009099.
49. Keenan PS, Normand SL, Lin Z, Drye EE, Bhat KR et al. (2008) An
administrative claims measure suitable for profiling hospital
performance on the basis of 30-day all-cause readmission rates among
patients with heart failure. Circ Cardiovasc Qual Outcomes 1: 29-37.
doi:10.1161/CIRCOUTCOMES.108.802686. PubMed: 20031785.
50. National Quality Forum (2008) National voluntary consensus standards
for hospital care 2007: performance measures - a consensus report.
Washington, DC: National Quality Forum
51. Centers for Medicare & Medicaid Services Hospital Pay-for-
Performance. Workgroup (2007); US Department of Health and Human
Services Medicare Hospitalvalue-based purchasing plan development,
issues paper, 1st public listening session. Washington, DC: Centers for
Medicare & Medicaid Services.
52. Rosamond WD, Chang PP, Baggett C, Johnson A, Bertoni AG et al.
(2012) Classification of heart failure in the atherosclerosis risk in
communities (ARIC) study: a comparison of diagnostic criteria. Circ
Cardiopulmonary Treatment of Heart Failure
PLOS ONE | www.plosone.org 10 October 2013 | Volume 8 | Issue 10 | e78222
Heart Fail 5: 152-159. doi:10.1161/CIRCHEARTFAILURE.111.963199.
PubMed: 22271752.
Cardiopulmonary Treatment of Heart Failure
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e78222
